Evidence map›Paper›PMID 41706398›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2026

Unveiling a new sequence type in high-risk clonal complexes of virulent carbapenem-resistant Pseudomonas aeruginosa carrying bla

Vitelhe Ferreira de Almeida, Vinicius Lopes Dias, Teresiama Velikkakam, Sabrina Royer, Elias Rodrigues de Almeida-Junior, Caio Augusto Martins Aires, André Oliveira Mota Junior, Isabella Macário Ferro Cavalcanti, Maria Amélia Vieira Maciel, Cristiane Silveira Brito and 1 more

Abstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Vitelhe Ferreira de AlmeidaLaboratory of Molecular Microbiology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.ORCID http://orcid.org/0000-0002-7142-4375
Vinicius Lopes DiasLaboratory of Molecular Microbiology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Teresiama VelikkakamLaboratory of Molecular Microbiology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Sabrina RoyerLaboratory of Molecular Microbiology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Elias Rodrigues de Almeida-JuniorLaboratory of Molecular Microbiology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Caio Augusto Martins AiresDepartment of Health Sciences, Federal University of the Semi-Arid Region - UFERSA, Mossoró, Brazil.
André Oliveira Mota JuniorLaboratory of Molecular Microbiology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Isabella Macário Ferro CavalcantiLaboratory of Microbiology and Immunology, Academic Center of Vitória (CAV), Federal University of Pernambuco (UFPE), Institute Keizo Asami (iLIKA- UFPE), Vitória de Santo Antão, Pernambuco, Brazil.
Maria Amélia Vieira MacielMedical Science Center, Federal University of Pernambuco, Recife, PE, Brazil.
Cristiane Silveira BritoLaboratory of Molecular Microbiology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil.
Rosineide Marques RibasLaboratory of Molecular Microbiology, Federal University of Uberlandia, Uberlandia, Minas Gerais, Brazil. rosi_ribas@yahoo.com.br.ORCID http://orcid.org/0000-0001-9295-6832

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brazil is a country with an approximate 50% prevalence rate of carbapenem-resistant Pseudomonas aeruginosa (CR-PA). Therefore, monitoring the spread of high-risk clones from complex genotypes of CR-PA isolates is crucial for developing effective strategies to control antimicrobial resistance. In the present study, we aimed to evaluate the dissemination of high-risk clones P. aeruginosa carrying blaKPC-2 in Brazil. In this study, 87 CR-PA isolates were analyzed for virulence (exoU, exoT, exoS, and exoY) and resistance (blaKPC, blaOXA-48, blaPDC, blaNDM, qnrA, and qnrB) markers, detected by PCR and further assessed by RT-qPCR for mexA, mexB, mexE, mexX, blaPDC, oprD, and ampC genes. Clonal relatedness of the isolates was evaluated using multilocus sequence typing (MLST) and Pulsed-Field Gel Electrophoresis. Most isolates were obtained from tracheal secretions (65%). Among the resistance genes evaluated, the prevalent was blaPDC-5 (88%). Additionally, these strains were found carrying important genes, including blaKPC-2 (12%) and blaOXA-48 (4%). No overexpression of efflux pump genes or the blaPDC and ampC genes was observed compared to the control strain (PAO1). Similarly, there was no reduction in oprD gene expression. The MLST analysis revealed that all evaluated strains belonged to novel sequence types (STs). These STs were associated with five different clonal complexes: ST5037, ST5040, ST5043 (CC244), ST5038 (CC155), ST5039 (CC235), ST5041 (CC277), ST5042 (CC639), and ST5044 (CC27). Eight new STs were identified in KPC-P. aeruginosa in Brazil. This finding suggests the need for consistent monitoring of KPC-producing P. aeruginosa to control the spread of high-risk clones in hospital settings.

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsPseudomonas aeruginosaPseudomonas InfectionsBrazilElectrophoresis, Gel, Pulsed-FieldGenotypeHumansMicrobial Sensitivity TestsMultilocus Sequence TypingVirulenceVirulence FactorsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsVirulence FactorsClonal complex CC244DisseminationEfflux pump genesHigh-risk clonesP. aeruginosa

Identifiers

PMID41706398
PMCPMC12917092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.